ArticleInternational journal of clinical and experimental pathology2019
Crosstalk between Hh and Wnt signaling promotes osteosarcoma progression.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 9 citations in OpenAlex.
- Hedgehog Signalling in Osteogenesis and Bone Metabolism: Molecular Mechanisms, Regulatory Networks and Implications for Skeletal Disease.Journal of cellular and molecular medicine · 2025Review
- Curcumin and Methotrexate: A Promising Combination for Osteosarcoma Treatment via Hedgehog Pathway Inhibition.International journal of molecular sciences · 2024Article
- Article
- Targeting hedgehog-driven mechanisms of drug-resistant cancers.Frontiers in molecular biosciences · 2023Review
- Inhibition of Gli2 suppresses tumorigenicity in glioblastoma stem cells derived from a de novo murine brain cancer model.Cancer gene therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOsteosarcoma (OS) is the most common primary malignant tumor of bone. Patients with localized osteosarcoma are routinely treated with chemotherapy and surgery. However, many patients eventually relapse after these treatments. Therefore, it is important and urgent to identify better therapeutic strategies. Hedgehog-GLI is responsible for the development of bone and tumorigenesis. Aberrant activation of GLI-2 is correlated with various malignancies including OS.
methodsRT-QPCR and western blot were performed to detect the expression of GLI-2 among human osteosarcoma cell lines U2OS, SaOS and human osteoblast cells HOB-c. siRNA or overexpression method were used to knock down/overexpress GLI-2 or β-catenin and MTS formazan generation method were applied to study the function of GLI-2 and β-catenin in the proliferation of OS cells.
resultsWe showed that GLI-2 is highly expressed in osteosarcoma cell lines. Knockdown of GLI-2 by siRNA decreases osteosarcoma cell proliferation. Further, we showed that knockdown of GLI-2 can decrease the protein level of β-catenin, and β-catenin depletion by siRNA could decrease the proliferation of OS cells. Interestingly, overexpression of β-catenin in GLI-2 knockdown cells partially increased proliferation.
conclusionThese findings suggest Hh/GLI-2-Wnt/β-catenin crosstalk is required for osteosarcoma cell proliferation. GLI-2 may play a role in the regulation of the expression of β-catenin in OS cells and β-catenin may function as downstream effector of crosstalk between Hh and Wnt signaling. GLI-2 may be exploited as a therapeutic target for the treatment of osteosarcoma patients.
Indexed as
Identifiers
31933884PMC6945176W3006623968What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.